Choice of Oral Anticoagulant Drug and the Antithrombotic Strategy in Patient with Atrial Fibrillation and Cirrhosis

OBJECTIVE To investigate the choice and safety of oral anticoagulation drugs in the treatment of patients with atrial fibrillation combined cirrhosis. METHODS By formulating the antithrombosis therapy plan for a patient after atrioseptopexy with atrial fibrillation and hepatitis B cirrhosis, the efficacy and status of safety evaluation of oral anticoagulation in treatment of atrial fibrillation combined cirrhosis according to the guidelines and literatures summarized and analyzed. RESULTS By comprehensive assessment of patient's situation, warfarin was discontinued, dabigatran 110 mg, bid combined with clopidogrel 75 mg, qd were used for 6 months, followed by dabigatran 110 mg, bid in long term anticoagulant therapy was adopted. CONCLUSION Thrombosis and bleeding shall be fully concerned in patient with atrial fibrillation and cirrhosis, and of individual antithrombotic therapy strategy will be developed accordingly. Atrial fibrillation and Child-Pugh A cirrhosis, new oral anticoagulants can be used; Child-Pugh C cirrhosis, oral anticoagulants are not recommended; Child-Pugh B cirrhosis with high risk of bleeding, a small dose of dabigatran etexilate can be used in long-term anticoagulation.